ADX-2191
Phase 3Small molecule
ADX-2191 is one of 80 small molecule programs targeting Lymphoma. It is currently in Phase 3.
3
Indications
3
Total Trials
1
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1ADX-2191
AAldeyra Therapeutics, Inc.
Phase 3
Blenoxane
SSequus Pharmaceuticals
Preclinical
Oncaspar
SServier
Preclinical
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ADX-2191. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAldeyra Therapeutics, Inc.